Trial Condition(s):

Prevention of venous thromboembolism after MOS

BAY59-7939, ER, Prototype IV

Bayer Identifier:

12571

ClinicalTrials.gov Identifier:

Not Available

EudraCT Number:

2010-022937-27

EU CT Number:

Not Available

Study Completed

Trial Purpose

Please see attached Study Results Summary below

Inclusion Criteria

No Inclusion Criteria Available

Exclusion Criteria

No Exclusion Criteria Available

Trial Summary

Enrollment Goal

N/A

Trial Dates

November2010

January2011

Phase

N/A

Could I receive a placebo?

Products

Xarelto (Rivaroxaban, BAY59-7939)

Accepts Healthy Volunteers

N/A

Where to Participate

Locations

Locations
Locations Bayer HealthCare Wuppertal, Germany, 42096	Contact Us: E-mail: [email protected] Phone: Not Available

Bayer HealthCare

Wuppertal, Germany, 42096

Contact Us:

E-mail: [email protected]

Phone: Not Available

Prevention of venous thromboembolism after MOS

Bayer Identifier:

ClinicalTrials.gov Identifier:

EudraCT Number:

EU CT Number:

Trial Purpose

Key Participation Requirements

sex

age

18 Years

55 Years

Inclusion Criteria

Exclusion Criteria

Inclusion Criteria

Exclusion Criteria

Trial Summary

Enrollment Goal

Trial Dates

Phase

Could I receive a placebo?

Products

Accepts Healthy Volunteers

Where to Participate

For details, please refer to trial results

Additional Information